Cover Image
市場調查報告書

瞬態電壓感受器陽離子通道亞族V/子類1:開發中產品分析

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364860
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
瞬態電壓感受器陽離子通道亞族V/子類1:開發中產品分析 Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 105 Pages
簡介

本報告提供以瞬態電壓感受器陽離子通道亞族V子類1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

瞬態電壓感受器陽離子通道亞族V子類1:概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Amorepacific Corporation
  • AnaBios Corporation
  • BCN Peptides, S.A.
  • Centrexion Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • DoNatur GmbH
  • Flex Pharma, Inc.
  • Grunenthal GmbH
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Neurim Pharmaceuticals Ltd
  • PharmEste
  • Pila Pharma AB
  • Sylentis S.A.U.
  • Toray Industries

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0154TDB

Summary

Global Markets Direct's, 'Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2016', provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) Overview
  • Therapeutics Development
    • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Stage of Development
    • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Therapy Area
    • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Indication
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Companies
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Products under Development by Universities/Institutes
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Amorepacific Corporation
    • AnaBios Corporation
    • BCN Peptides, S.A.
    • Centrexion Corporation
    • Daewoong Pharmaceutical Co., Ltd.
    • DoNatur GmbH
    • Flex Pharma, Inc.
    • Grunenthal GmbH
    • Johnson & Johnson
    • Kyowa Hakko Kirin Co., Ltd.
    • Neurim Pharmaceuticals Ltd
    • PharmEste
    • Pila Pharma AB
    • Sylentis S.A.U.
    • Toray Industries, Inc.
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles
    • AMG-986 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1119 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • capsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • capsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • capsaicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGS-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CGS-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMX-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DD-04107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-05195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLX-787 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39729209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-685 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-6860 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-14028 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHE-575 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QX-314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Analgesia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Overactive Bladder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEND-0501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Projects
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products
  • Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Featured News & Press Releases
  • May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps
    • Apr 19, 2016: Flex Pharma's Positive Human NLC Study Selected for Presentation at AAN Annual Meeting
    • Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
    • Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting
    • Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study
    • Jan 06, 2016: Enrollment Completed in Flex Pharma's Exploratory Human Nocturnal Leg Cramp Study
    • Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic
    • Nov 23, 2015: CapGenesis Announces Start of Dosing in an Exploratory Study of CGS-125 for Management of Osteoarthritic Knee Pain
    • Nov 19, 2015: Astellas Announces Results from the First Head to Head Study Comparing QUTENZA (Capsaicin 8% Patch) with Current Standard of Care in Patients with Peripheral Neuropathic Pain
    • Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate
    • Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps
    • Jul 28, 2015: Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings
    • Jul 07, 2015: Flex Pharma Announces Reduction of Muscle Cramping in Athletes
    • May 04, 2015: NSF Approves Flex Pharma's Proprietary Formulation under NSF's Certified for Sport Program
    • Apr 27, 2015: Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Amorepacific Corporation, H1 2016
  • Pipeline by AnaBios Corporation, H1 2016
  • Pipeline by BCN Peptides, S.A., H1 2016
  • Pipeline by Centrexion Corporation, H1 2016
  • Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by DoNatur GmbH, H1 2016
  • Pipeline by Flex Pharma, Inc., H1 2016
  • Pipeline by Grunenthal GmbH, H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
  • Pipeline by PharmEste, H1 2016
  • Pipeline by Pila Pharma AB, H1 2016
  • Pipeline by Sylentis S.A.U., H1 2016
  • Pipeline by Toray Industries, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Dormant Projects (Contd..5), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top